Benjamin L Blend, M.D. Pathology - Anatomic Pathology & Clinical Pathology Medicare: Not Enrolled in Medicare Practice Location: 931 Highland Blvd, Suite 3220, Bozeman, MT 59715 Phone: 406-587-1261 Fax: 406-587-3928 |
News Archive
SensAble Technologies, Inc®, a leading provider of touch-enabled 3D modeling systems, dental CAD/CAM solutions and haptic devices, has announced Release 3 of the SensAble Dental Lab System (SDLS), with significant enhancements to this integrated system for creating dental restorations efficiently and more cost-effectively.
Tengion, Inc. presented new research data yesterday in a podium presentation at the 2nd Annual Symposium on Stem Cell Translation of the International Society for Cellular Therapy (ISCT) in San Francisco. The presentation highlighted new results from Tengion's Neo-Kidney Augment development program demonstrating success with an autologous cellular therapy approach to kidney regeneration in a rodent model of obesity, diabetes and hypertension.
Traumatic stress is a key factor associated with depression among immigrant mothers from Central America, reports a study in Family and Community Health: The Journal of Health Promotion & Maintenance – part of a special theme issue devoted to "Family Health in Hispanic Communities" that includes guest editors Paul Branscum, PhD, RD, and Daphne C. Hernandez, PhD, MSEd The journal is published in the Lippincott portfolio by Wolters Kluwer.
Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer gene analysis to routine clinical care, and Dana-Farber Cancer Institute today announced the Nature Medicine publication of results from their collaborative next-generation sequencing (NGS) study to assay cancer-relevant genes in 24 non-small cell lung cancer (NSCLC) and 40 colorectal cancer (CRC) cases.
Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a and ribavirin in a treatment experienced, hepatitis C null responder patient population. Safety, tolerability, and antiviral activity of the triple combination will be assessed after up to 48 weeks of therapy.
› Verified 6 days ago